Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

In recognition of World Obesity Day,�Ivim Health is proud to advocate on behalf of patients on their health journeys by providing personalized and effective care, guided by medical professionals who ...